Memo Therapeutics secures additional funding, Series C financing now at CHF 45 million

Memo Therapeutics AG, a biotech company based in Switzerland, has successfully raised an additional CHF 20 million in an extension of its Series C financing, bringing the total amount raised to CHF 45 million. This funding will be used to expand the Phase II trial of its lead asset, AntiBKV, to become the largest study ever conducted for BK virus infection in kidney transplantation.

The BK virus can become reactivated in immunosuppressed kidney transplant patients, leading to severe complications. With no disease-modifying therapies currently available, Memo Therapeutics aims to address this unmet medical need with its highly potent anti-BK virus antibody.

Erik van den Berg, CEO of Memo Therapeutics, expressed his excitement about the financing, stating that it provides further validation of their clinical strategy to bring AntiBKV to patients as quickly as possible. With FDA fast track status already obtained for the product, the company is looking forward to advancing the development of AntiBKV.

New investors Ysios Capital and Kurma Partners participated in the extension round, joining existing investors in supporting Memo Therapeutics’ mission. The company’s pipeline also includes pre-clinical assets in cancer and viral infections, leveraging its antibody discovery platform to develop best-in-class humanized antibodies.

The funding will further support Memo Therapeutics in its efforts to address the urgent need for a treatment for BK virus infection in kidney transplant recipients, as well as other viral infections and oncology indications.